Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(17%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

50%

Ph not_applicable

17%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 2Efficacy & side effects

2(33.3%)

Phase 3Large-scale testing

3(50.0%)

N/ANon-phased studies

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Withdrawn1

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 22 (33.3%)

Phase 33 (50.0%)

N/A1 (16.7%)

Trials by Status

completed350%

withdrawn117%

active_not_recruiting117%

unknown117%

Recent Activity

1 active trials

Showing 5 of 6

active_not_recruitingphase_3

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844

withdrawnnot_applicable

Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke?

NCT03230370

completedphase_2

Clinical Trials (6)

Showing 6 of 6 trials

NCT06564844Phase 3

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Active Not Recruiting

NCT03230370Not Applicable

Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke?

Withdrawn

NCT02903498Phase 2

The Maintenance Treatment of UFT in Advanced Gastric Cancer

Completed

NCT01225744Phase 2

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

Completed

NCT00209742Phase 3

Randomized Phase III Adjuvant Study for Stage III Colorectal Cancer